No Data
No Data
Piper Lists Eight Defensive Biotechs to Face Market Volatility
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
BioCryst Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
BioCryst Pharmaceuticals Price Target Raised to $16.00/Share From $15.00 by JMP Securities
BioCryst Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30